Navigation Links
Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
Date:5/13/2008

Company Now Has Four Phase 2 Trials Underway

MONTVALE, N.J., May 13 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) has dosed the first patient in a 160-patient Phase 2 study of alagebrium in patients with diastolic heart failure. BREAK (Beginning a Randomized Evaluation of the A.G.E. [Advanced Glycation End Product] Breaker Alagebrium in Diastolic Heart Failure) is a randomized, double-blind, placebo controlled study to assess the effect of six months of oral treatment with 400mg (200mg twice daily) alagebrium versus placebo in patients diagnosed with diastolic heart failure as verified by echocardiography. The trial will ultimately enroll 80 patients per cohort and be conducted in as many as 25 centers in the United States. Investigators intend that at least half of the study subjects will have diabetes mellitus. The primary efficacy measure of the study is improvement of exercise tolerance as assessed by the six-minute walk test, an accepted regulatory endpoint. In addition, there will be a number of secondary and tertiary measurements including the effect on carboxymethyllysine (CML), a biomarker of A.G.E., against which Synvista has developed a proprietary monoclonal antibody, 4G9, which can be developed into an in-vitro diagnostic test.

"This is a very important study for alagebrium. By looking at the results of the BREAK study along with our BENEFICIAL study in systolic heart failure, we will have a better understanding of the role of A.G.E.s in heart failure," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, developer of alagebrium. "Based on what we learn from these studies, there is immense potential to expand the scope of treatment modal
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
3. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
6. Synvista Therapeutics to be Featured on Wallst.net
7. Synvista Therapeutics to Present at the BIO InvestorForum 2007
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
10. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... Park Systems announced that they ... 2015 at 9am PST. The webinar will focus on the methods and materials for ... printing, additive manufacturing is a broad term that encompasses “addition or fusion” of materials ...
(Date:9/2/2015)... Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical testing, ... LLC, a consulting firm with expertise in medical device products/processes development, design ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
Breaking Biology Technology:Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
...  Oxford Finance LLC ("Oxford"), a specialty finance firm that ... companies, today announced a $15 million round of debt ... which was awarded to NanoString from both Oxford and ... term loan and a $2 million revolving line of ...
... Mass. and TORONTO, April 3, 2012  Generex Biotechnology Corporation ... Cancer Research (AACR) chose to spotlight a presentation on ... immunotherapeutic vaccine to prevent relapse in patients who have ... a press conference.  The annual AACR meeting is one ...
... 2012 Echo Therapeutics, Inc. (Nasdaq: ECTE ... as a non-invasive, wireless, transdermal continuous glucose monitoring system ... is pleased to announce that its most recently completed ... Scientific Sessions of the American Diabetes Association (ADA) which ...
Cached Biology Technology:Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 3Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 2Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 3Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 4Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association 2Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association 3
(Date:9/1/2015)... 1, 2015  Automation and pre-processing are reducing ... screening. This is the first step toward a ... become unintrusive. An assortment of portal scanners, biometric ... investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( http://www.frost.com/nf2b ...
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... connection between genes that could hold the key to ... similar genetics to humans, scientists from Huntsman Cancer Institute ... one associated with aging, the other with certain types ... affect how these genes operate, possibly increasing lifespan in ...
... tasty beetles on a quiet day is simple for bats ... it must be like trying to locate rustling treats just ... almost impossible to pick out a centipede,s footsteps as a ... their prey by sound alone cope in our increasingly noisy ...
... at Purdue University suggests synthetic carbon molecules called ... being accumulated in animal tissue, but the molecules ... reducing their possible environmental dangers. Buckyballs may ... from drug-delivery vehicles for cancer therapy to ultrahard ...
Cached Biology News:Longevity, cancer and diet connected: New research in worms could apply to humans 2Bats pick up rustling sounds against highway background noise 2'Buckyballs' have high potential to accumulate in living tissue 2'Buckyballs' have high potential to accumulate in living tissue 3
... BAC (100+kb), fosmid (40kb), and large plasmid ... any othe BAC vector. On command 20-50 ... easy recombinant DNA purification. Available with blue-white ... vectors for the highest insert stability. Kits ...
Request Info...
CHIMAERIC HUMAN IgA2 ANTI NP...
nuclear cap binding protein subunit 1, 80kDa, mRNA...
Biology Products: